Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Statin intolerance is far less common than previously reported, according to a new meta-analysis, with data on more than 4 million adults from around the world, looking at reported statin adverse effects.
The study puts the prevalence of statin intolerance at 6% to 10%, meaning that statin intolerance is "overestimated and overdiagnosed" in most cases, Maciej Banach, MD, PhD, from the Medical University of Lodz and the University of Zielona Góra, Poland, said in a news release.
It also means that "around 93% of patients on statin therapy can be treated effectively, with very good tolerability and without any safety issues," Banach added.
The study, conducted on behalf of the Lipid and Blood Pressure Meta-Analysis Collaboration and the International Lipid Expert Panel, was published online February 16 in the European Heart Journal.
The study puts the prevalence of statin intolerance at 6% to 10%, meaning that statin intolerance is "overestimated and overdiagnosed" in most cases, Maciej Banach, MD, PhD, from the Medical University of Lodz and the University of Zielona Góra, Poland, said in a news release.
It also means that "around 93% of patients on statin therapy can be treated effectively, with very good tolerability and without any safety issues," Banach added.
The study, conducted on behalf of the Lipid and Blood Pressure Meta-Analysis Collaboration and the International Lipid Expert Panel, was published online February 16 in the European Heart Journal.
Statin Intolerance 'Overestimated and Overdiagnosed'
Less than 10% of patients experience statin intolerance, a new meta-analysis shows, meaning that the vast majority of patients can be treated effectively, with very good tolerability, researchers say.
www.medscape.com